Environ Toxicol Pharmacol 2011,31(1):250–257.PubMedCrossRef 14. Rekhadevi PV, Sailaja N, Chandrasekhar M, et al.: Genotoxicity assessment in oncology nurses handling anti-neoplastic drugs. Mutagenesis 2007, 6:395–401.CrossRef 15. Rombaldi F, Cassini C, Salvador M, et al.: Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week. LY2835219 datasheet Mutagenesis 2009, 24:143–148.PubMedCrossRef 16. International Agency for Research on Cancer: Monographs on the evaluation of the carcinogenic risk of chemicals to humans: pharmaceutical drugs.
IARC, Lyon, France; 2001. 17. Lipp. Cardiotoxicity of cytotoxic drugs: Anticancer drug toxicity: prevention, management and clinical pharmacokinetics. Marcel Dekker, New York; 1999:471–488. 18. Shaikh AY, Shih JA: Chemotherapy-induced cardiotoxicity. Curr Heart Fail Rep 2012,9(2):117–127.PubMedCrossRef 19. Albini A, Pennesi G, Donatelli F, et al.: Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010, 102:14–25.PubMedCrossRef 20. Yeh ET, Copanlisib Tong AT, Lenihan
DJ, et al.: Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004, 109:3122–3131.PubMedCrossRef 21. Chiusa M, Timolati F, Perriard JC, et al.: Sodium nitroprusside induces cell death and cytoskeleton degradation in adult rat cardiomyocytes in vitro: implications for anthracycline-induced cardiotoxicity. Eur J Histochem 2012,56(2):e15.PubMedCrossRef 22. Wojtacki J, Lewicka-Nowack E, Lesniewski-Kmak K: Anthracycline-induced cardiotoxicity: clinical EPZ5676 ic50 course, risk factors, pathogenesis, detection and prevention—review of the literature. Med Sci Monit 2000, 6:411–420.PubMed 23. Sawyer DB, Zuppinger C, Miller TA, et al.: Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced
cardiotoxicity. Circulation 2002, 105:1551–1554.PubMedCrossRef 24. Minotti G, Cairo G, Monti E: Role of iron in anthracycline cardiotoxicity: new tunes for an old song? FASEB J 1999,13(2):199–212.PubMed 25. Elliott P: Pathogenesis selleck compound of cardiotoxicity induced by anthracyclines. Semin Oncol 2006, 33:S2-S7.PubMedCrossRef 26. Jensen SA, Sørensen JB: 5-Fluorouracil-based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. Cancer Chemother Pharmacol 2012,69(1):57–64.PubMedCrossRef 27. Anand AJ: Fluorouracil cardiotoxicity. Ann Pharmacother 1994, 28:374–378.PubMed 28. Chiosi E, Spina A, Sorrentino A, et al.: Change in TNF- receptor expression is a relevant event in doxorubicin-induced H9c2 cardiomyocyte cell death. J Interferon Cytokine Res 2007, 27:589–597.PubMedCrossRef 29.